Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of the Combination of Gemcitabine (Gemzar) Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines an/or Taxanes

NCT00192101 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00192101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00192101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of the Combination of Gemcitabine (Gemzar) Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines an/or Taxanes
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2004
Completion date
July 31, 2005
Enrollment
100
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer